A Two-Year, Safety Evaluation of Paliperidone Extended-Release in the Treatment of Adolescents (12-17 Years) with Schizophrenia: An Open-Label, Flexible-Dose Study

New Research Poster Presentation 5.59
A Two-Year, Safety Evaluation of Paliperidone Extended-Release in the Treatment of Adolescents (12-17 Years) with Schizophrenia: An Open-Label, Flexible-Dose Study

Friday, October 25, 2013

Adam J. Savitz, MD, PhD, Titusville, NJ

Rosanne Lane, Titusville, NJ

Isaac F. Nuamah, PhD, Clinical Biostatistics, Titusville, NJ

Jaskaran B. Singh, MD, Neuroscience, Titusville, NJ

David W. Hough, MD, Central Nervous System, Titusville, NJ

Srihari Gopal, MD, Neuroscience Therapeutic Area, Titusville, NJ